Based on the earnings transcript, Merck & Co. reported strong third-quarter financial results, with revenue growth of 1% year-over-year and EPS growth of 18%. The company's pipeline of promising medicines and vaccines, including COVID-19 therapies, is a significant driver of growth. The stock is likely to experience short-term pressure due to the impact of the pandemic on certain business units, but the company's strong operational performance and long-term growth prospects suggest a positive outlook. The stock is likely to experience short-term pressure due to the impact of the pandemic on certain business units, but the company's strong operational performance and long-term growth prospects suggest a positive outlook. The stock is likely to experience short-term pressure due to the impact of the pandemic on certain business units, but the company's strong operational performance and long-term growth prospects suggest a positive outlook. The stock is likely to experience short-term pressure due to the impact of the pandemic on certain business units, but the company's strong operational performance and long-term growth prospects suggest a positive outlook.

-1